Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target

SK Kolluri, UH Jin, S Safe - Archives of toxicology, 2017 - Springer
The aryl hydrocarbon receptor (AhR) was initially identified as the receptor that binds and
mediates the toxic effects induced by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) and …

[HTML][HTML] The functions and clinical significance of circRNAs in hematological malignancies

X Zhou, L Zhan, K Huang, X Wang - Journal of hematology & oncology, 2020 - Springer
With covalently closed circular structures, circular RNAs (circRNAs) were once
misinterpreted as by-products of mRNA splicing. Being abundant, stable, highly conserved …

Cancer treatment and survivorship statistics, 2019

KD Miller, L Nogueira, AB Mariotto… - CA: a cancer journal …, 2019 - Wiley Online Library
The number of cancer survivors continues to increase in the United States because of the
growth and aging of the population as well as advances in early detection and treatment. To …

Cancer treatment and survivorship statistics, 2016

KD Miller, RL Siegel, CC Lin… - CA: a cancer journal …, 2016 - Wiley Online Library
The number of cancer survivors continues to increase because of both advances in early
detection and treatment and the aging and growth of the population. For the public health …

Cancer statistics, 2018

RL Siegel, KD Miller, A Jemal - CA: a cancer journal for …, 2018 - Wiley Online Library
Abstract Each year, the American Cancer Society estimates the numbers of new cancer
cases and deaths that will occur in the United States and compiles the most recent data on …

Cancer statistics, 2015.

RL Siegel, KD Miller, A Jemal - CA: a cancer journal for …, 2015 - search.ebscohost.com
Abstract Each year the American Cancer Society estimates the numbers of new cancer
cases and deaths that will occur in the United States in the current year and compiles the …

The e13a2 BCR‐ABL transcript negatively affects sustained deep molecular response and the achievement of treatment‐free remission in patients with chronic …

M D'Adda, M Farina, F Schieppati, E Borlenghi… - Cancer, 2019 - Wiley Online Library
Background Stopping tyrosine kinase inhibitor (TKI) treatment has become a realistic and
safe objective for patients who have chronic myeloid leukemia (CML). Both a sustained …

[HTML][HTML] Immunotherapy approaches for hematological cancers

OL Lanier, E Pérez-Herrero, A PD'Andrea, K Bahrami… - Iscience, 2022 - cell.com
Hematological cancers such as leukemia, lymphoma, and multiple myeloma have
traditionally been treated with chemo and radiotherapy approaches. Introduction of …

Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome …

A Guérin, L Chen, R Ionescu-Ittu… - … medical research and …, 2014 - Taylor & Francis
Objective: Chronic myeloid leukemia (CML) treatment relies on tyrosine kinase inhibitors
(TKIs), but their use can be associated with low-grade adverse events (AEs). This analysis …

The war on cancer: are we winning?

MJ Duffy - Tumor Biology, 2013 - Springer
Of all the diseases affecting humankind, cancer is one of the most difficult to treat and cure.
One of the main reasons for this difficulty relates to the fact that cancer is not a single …